glp-1 agonist and dpp-4 inhibitor inhibitors GLP-1RAs: cardiovascular safety and benefits DPP4 Inhibitor Mechanism of Action
Description
This made semaglutide the first GLP-1 RA approved specifically for kidney disease protection, paralleling the role of SGLT2 inhibitors in renal care
Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial
Outcomes were tracked from 3 months after the index date to a maximum of 5 years
this review essentially scratches the surface of some of these effects, that GLP-1 meds have on the immune system
Drugs 79 , 219230 (2019)
